Cargando…

Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism

IMPORTANCE: Despite access to routine laboratory evaluation, primary hyperparathyroidism (PHP) remains underdiagnosed and undertreated. OBJECTIVE: To determine the consequences associated with missed diagnoses and prolonged time to diagnosis and treatment of PHP. DESIGN, SETTING, AND PARTICIPANTS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenz, F. Jeffrey, Beauchamp-Perez, Francis, Manni, Andrea, Chung, Thomas, Goldenberg, David, Goyal, Neerav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857508/
https://www.ncbi.nlm.nih.gov/pubmed/36574247
http://dx.doi.org/10.1001/jamanetworkopen.2022.48332
_version_ 1784873885074718720
author Lorenz, F. Jeffrey
Beauchamp-Perez, Francis
Manni, Andrea
Chung, Thomas
Goldenberg, David
Goyal, Neerav
author_facet Lorenz, F. Jeffrey
Beauchamp-Perez, Francis
Manni, Andrea
Chung, Thomas
Goldenberg, David
Goyal, Neerav
author_sort Lorenz, F. Jeffrey
collection PubMed
description IMPORTANCE: Despite access to routine laboratory evaluation, primary hyperparathyroidism (PHP) remains underdiagnosed and undertreated. OBJECTIVE: To determine the consequences associated with missed diagnoses and prolonged time to diagnosis and treatment of PHP. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective cohort study of patients older than 40 years with 2 instances of hypercalcemia during 2010 to 2020 and 3 years of follow-up. Patients were recruited from 63 health care organizations in the TriNetX Research Network. Data analysis was performed from January 2010 to September 2020. EXPOSURES: Elevated serum calcium. MAIN OUTCOMES AND MEASURES: Existing symptoms and diagnoses associated with PHP (osteoporosis, fractures, urolithiasis, major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, constipation, insomnia, polyuria, weakness, abdominal pain, headache, nausea, amnesia, and gallstones) compared in patients deemed high-risk and without a diagnosis and matched controls, and those who experienced times from documented hypercalcemia to diagnosis and diagnosis to treatment within or beyond 1 year. RESULTS: There were 135 034 patients analyzed (96 554 women [72%]; 28 892 Black patients [21%] and 88 010 White patients [65%]; 3608 Hispanic patients [3%] and 98 279 non-Hispanic patients [73%]; mean [SD] age, 63 [10] years). Two groups without a documented diagnosis of PHP were identified as high risk: 20 176 patients (14.9%) with parathyroid hormone greater than or equal to 50 pg/mL and 24 905 patients (18.4%) with no parathyroid hormone level obtained or recorded explanation for hypercalcemia. High-risk patients experienced significantly increased rates of all associated symptoms and diagnoses compared with matched controls. Just 9.7% of those with hypercalcemia (13 136 patients) had a diagnosis of PHP. Compared with individuals who received a diagnosis within 1 year of hypercalcemia, those whose workup exceeded 1 year had significantly increased rates of major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, polyuria, weakness, abdominal pain, and headache at 3 years. The rate of osteoporosis increased from 17.1% (628 patients) to 25.4% (935 patients) over the study period in the group with delayed diagnosis. Among those with a diagnosis, 5280 patients (40.2%) underwent parathyroidectomy. Surgery beyond 1 year of diagnosis was associated with significantly increased rates of osteoporosis and hypertension at 3 years after diagnosis compared with those treated within 1 year. CONCLUSIONS AND RELEVANCE: Many patients were at high risk for PHP without a documented diagnosis. Complications in these patients, as well as those who received a diagnosis after prolonged workup or time to treatment, resulted in patient harm. System-level interventions are necessary to ensure proper diagnosis and prompt treatment of PHP.
format Online
Article
Text
id pubmed-9857508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-98575082023-02-01 Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism Lorenz, F. Jeffrey Beauchamp-Perez, Francis Manni, Andrea Chung, Thomas Goldenberg, David Goyal, Neerav JAMA Netw Open Original Investigation IMPORTANCE: Despite access to routine laboratory evaluation, primary hyperparathyroidism (PHP) remains underdiagnosed and undertreated. OBJECTIVE: To determine the consequences associated with missed diagnoses and prolonged time to diagnosis and treatment of PHP. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective cohort study of patients older than 40 years with 2 instances of hypercalcemia during 2010 to 2020 and 3 years of follow-up. Patients were recruited from 63 health care organizations in the TriNetX Research Network. Data analysis was performed from January 2010 to September 2020. EXPOSURES: Elevated serum calcium. MAIN OUTCOMES AND MEASURES: Existing symptoms and diagnoses associated with PHP (osteoporosis, fractures, urolithiasis, major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, constipation, insomnia, polyuria, weakness, abdominal pain, headache, nausea, amnesia, and gallstones) compared in patients deemed high-risk and without a diagnosis and matched controls, and those who experienced times from documented hypercalcemia to diagnosis and diagnosis to treatment within or beyond 1 year. RESULTS: There were 135 034 patients analyzed (96 554 women [72%]; 28 892 Black patients [21%] and 88 010 White patients [65%]; 3608 Hispanic patients [3%] and 98 279 non-Hispanic patients [73%]; mean [SD] age, 63 [10] years). Two groups without a documented diagnosis of PHP were identified as high risk: 20 176 patients (14.9%) with parathyroid hormone greater than or equal to 50 pg/mL and 24 905 patients (18.4%) with no parathyroid hormone level obtained or recorded explanation for hypercalcemia. High-risk patients experienced significantly increased rates of all associated symptoms and diagnoses compared with matched controls. Just 9.7% of those with hypercalcemia (13 136 patients) had a diagnosis of PHP. Compared with individuals who received a diagnosis within 1 year of hypercalcemia, those whose workup exceeded 1 year had significantly increased rates of major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, polyuria, weakness, abdominal pain, and headache at 3 years. The rate of osteoporosis increased from 17.1% (628 patients) to 25.4% (935 patients) over the study period in the group with delayed diagnosis. Among those with a diagnosis, 5280 patients (40.2%) underwent parathyroidectomy. Surgery beyond 1 year of diagnosis was associated with significantly increased rates of osteoporosis and hypertension at 3 years after diagnosis compared with those treated within 1 year. CONCLUSIONS AND RELEVANCE: Many patients were at high risk for PHP without a documented diagnosis. Complications in these patients, as well as those who received a diagnosis after prolonged workup or time to treatment, resulted in patient harm. System-level interventions are necessary to ensure proper diagnosis and prompt treatment of PHP. American Medical Association 2022-12-27 /pmc/articles/PMC9857508/ /pubmed/36574247 http://dx.doi.org/10.1001/jamanetworkopen.2022.48332 Text en Copyright 2022 Lorenz FJ et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Lorenz, F. Jeffrey
Beauchamp-Perez, Francis
Manni, Andrea
Chung, Thomas
Goldenberg, David
Goyal, Neerav
Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title_full Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title_fullStr Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title_full_unstemmed Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title_short Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism
title_sort analysis of time to diagnosis and outcomes among adults with primary hyperparathyroidism
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857508/
https://www.ncbi.nlm.nih.gov/pubmed/36574247
http://dx.doi.org/10.1001/jamanetworkopen.2022.48332
work_keys_str_mv AT lorenzfjeffrey analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism
AT beauchampperezfrancis analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism
AT manniandrea analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism
AT chungthomas analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism
AT goldenbergdavid analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism
AT goyalneerav analysisoftimetodiagnosisandoutcomesamongadultswithprimaryhyperparathyroidism